2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER_GOV
1
OTHER
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Hepatocellular
147
Carcinoma, Renal Cell
37
Parkinson Disease 4, Autosomal Dominant Lewy Body
31
Neoplasms
28
Cholangiocarcinoma
26
Endometrial Neoplasms
19
Thyroid Neoplasms
17
Liver Neoplasms
17
Melanoma
15
Stomach Neoplasms
13
Carcinoma, Non-Small-Cell Lung
13
Biliary Tract Neoplasms
13
Recurrence
9
Neoplasm Metastasis
9
Squamous Cell Carcinoma of Head and Neck
8
Ovarian Neoplasms
8
Breast Neoplasms
8
Uterine Cervical Neoplasms
7
Triple Negative Breast Neoplasms
5
Thyroid Carcinoma, Anaplastic
5
Small Cell Lung Carcinoma
5
Neuroendocrine Tumors
5
Esophageal Squamous Cell Carcinoma
5
Colorectal Neoplasms
5
Pancreatic Neoplasms
4
Kidney Neoplasms
4
Carcinoma, Transitional Cell
4
Carcinoma
4
Adenocarcinoma
4
Thyroid Cancer, Papillary
3
Interventions
Cyclophosphamide
7
pembrolizumab
6
Radiotherapy
6
Cisplatin
6
Sunitinib
5
Carboplatin
5
Paclitaxel
4
Thymectomy
3
130-nm albumin-bound paclitaxel
3
selinexor
2
lenvatinib
2
fludarabine
2
Taxes
2
Robotic Surgical Procedures
2
Ramucirumab
2
Prednisone
2
Pemetrexed
2
Octreotide
2
Nivolumab
2
N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide
2
Methylprednisolone
2
Imatinib Mesylate
2
Etoposide
2
Erlotinib Hydrochloride
2
Drug Therapy
2
Doxorubicin
2
Chemoradiotherapy
2
Celecoxib
2
zimberelimab
1
vorolanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Thymoma
×
lenvatinib
×
Clear all
NCT04710628
2026-02-19
PECATI
MedSIR
Phase 2
Completed
43 enrolled
NCT05832827
2023-10-23
Artemis
National Cancer Center, Japan
Phase 2
Recruiting
35 enrolled